Genexine, Inc. (KOSDAQ:095700)
2,675.00
-80.00 (-2.90%)
Aug 12, 2026, 2:40 PM KST
Genexine Revenue
Genexine had revenue of 2.07B KRW in the quarter ending March 31, 2024, with 199.63% growth. This brings the company's revenue in the last twelve months to 5.81B, down -3.50% year-over-year. In the year 2023, Genexine had annual revenue of 4.43B, down -72.57%.
Revenue (ttm)
5.81B
Revenue Growth
-3.50%
P/S Ratio
21.57
Revenue / Employee
67.53M
Employees
86
Market Cap
125.30B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4.43B | -11.71B | -72.57% |
| Dec 31, 2022 | 16.14B | -20.69B | -56.18% |
| Dec 31, 2021 | 36.83B | 18.28B | 98.61% |
| Dec 31, 2020 | 18.54B | 7.24B | 64.06% |
| Dec 31, 2019 | 11.30B | 5.05B | 80.80% |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2009 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bioneer | 338.01B |
| Macrogen | 199.60B |
| JETEMA, | 77.07B |
| HLB Therapeutics | 67.56B |
| Prestige BioPharma | 16.21B |
| Anterogen.Co.,Ltd. | 8.06B |
| iNtRON Biotechnology | 5.74B |
| MedPacto | 4.79B |